Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pingxiao capsule real-world study after chemotherapy for triple-negative breast cancer
ChiCTR2100044664Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Pingxiao in triple-negative breast cancer (TNBC) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
Pingxiao
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2100044664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044664.